Literature DB >> 9627932

Comparison of the immunological and protective responses elicited by microencapsulated formulations of the F1 antigen from Yersinia pestis.

K M Reddin1, T J Easterbrook, S M Eley, P Russell, V A Mobsby, D H Jones, G H Farrar, E D Williamson, A Robinson.   

Abstract

Purified native F1 antigen from Yersinia pestis was used to assess controlled-release vaccine delivery systems in poly(lactide-co-glycolide) (PLG) microparticles and liposomes. Antigen encapsulated in PLG microparticles induced high serum titres when injected i.p. in mice: mucosal IgA was also detected. Mice immunized with F1 in Alhydrogel or PLGs were protected against subcutaneous challenge with Y. pestis. F1 antigen surface-labelled onto liposome vesicles stimulated high serum titres in Balb/c mice and also induced a mucosal response: F1-labelled liposomes protected mice against challenge with up to 1 x 10(5) organisms. These findings indicate that a significant immune response is induced by immunizing with F1 formulated in PLGs and liposomes and that protection was achieved after only one dose.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9627932     DOI: 10.1016/s0264-410x(97)00305-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Humoral and cellular immune responses to Yersinia pestis infection in long-term recovered plague patients.

Authors:  Bei Li; Chunhong Du; Lei Zhou; Yujing Bi; Xiaoyi Wang; Li Wen; Zhaobiao Guo; Zhizhong Song; Ruifu Yang
Journal:  Clin Vaccine Immunol       Date:  2011-12-21

Review 2.  Plague Vaccines: Status and Future.

Authors:  Wei Sun
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

3.  Repertoire of HLA-DR1-restricted CD4 T-cell responses to capsular Caf1 antigen of Yersinia pestis in human leukocyte antigen transgenic mice.

Authors:  Julie A Musson; Rebecca Ingram; Guillaume Durand; Stephanie Ascough; Emma L Waters; M Gillian Hartley; Timothy Robson; Bernard Maillere; E Diane Williamson; Shiranee Sriskandan; Daniel Altmann; John H Robinson
Journal:  Infect Immun       Date:  2010-07-26       Impact factor: 3.441

Review 4.  Protecting against plague: towards a next-generation vaccine.

Authors:  E D Williamson; P C F Oyston
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

Review 5.  Plague vaccine: recent progress and prospects.

Authors:  Wei Sun; Amit K Singh
Journal:  NPJ Vaccines       Date:  2019-02-18       Impact factor: 9.399

Review 6.  Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design.

Authors:  Emily M Plummer; Marianne Manchester
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010-09-24

7.  Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro.

Authors:  Yiu Wing Kam; François Kien; Anjeanette Roberts; Yan Chung Cheung; Elaine W Lamirande; Leatrice Vogel; Shui Ling Chu; Jane Tse; Jeannette Guarner; Sherif R Zaki; Kanta Subbarao; Malik Peiris; Béatrice Nal; Ralf Altmeyer
Journal:  Vaccine       Date:  2006-08-22       Impact factor: 3.641

8.  Development of Yersinia pestis F1 antigen-loaded microspheres vaccine against plague.

Authors:  Shih-shiung Huang; I-Hsun Li; Po-da Hong; Ming-kung Yeh
Journal:  Int J Nanomedicine       Date:  2014-02-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.